



MAYNE PHARMA TO HOST INTERACTIVE INVESTOR EDUCATION WEBINAR ON WOMEN'S HEALTH & DERMATOLOGY BUSINESSES

23 October 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX), announces an upcoming interactive investor education webinar discussing the Company's US Women's Health and Dermatology segments, including insights from several key US executives with strategic and operational oversight for each business.

In FY24, Women's Health generated revenue of \$142.8 million (up 131% on the prior corresponding period (pcp)) and Dermatology revenue increased by 207% to \$174.9 million versus the pcp. Combined, both segments generated an increase in direct contribution in FY24 of \$128.2 million, representing a major improvement on FY23. Approximately 65% of FY24 sales in the United States were from Mayne Pharma's innovative portfolio of branded medicines.

Mayne Pharma's CEO Shawn Patrick O'Brien and CFO Aaron Gray, along with Women's Health executives Tony Ramy, VP Women's Health, Chad Turner, VP Marketing Women's Health and Dermatology executives Meredith Gambill, VP Dermatology Sales and Daniel Moore, Executive Vice President, Specialty Products and Patient Solutions will present to investors, with an interactive Q&A session following the presentation for each business segment. The event will be moderated by Tom Duthy, Investor Relations. The event is scheduled to run for 1 hour 15 minutes.

Details of the Investor Education Webinar are below:

Date: Wednesday 30 October 2024 (AEDT) / Tuesday 29 October US EDT

Time: 8.45am Australian Eastern Daylight Time (AEDT) / 5.45pm US Eastern Daylight Time (EDT)

Registration: <https://s1.c-conf.com/diamondpass/10042891-v7qogf.html>

Investors can submit questions in advance or on the day to ir@maynepharma.com. An interactive Q&A is available via the webinar platform during the live presentation as well. The Company will also utilise an operator assisted platform for questions.

A webinar recording will be made available via the Company's website at: <https://www.maynepharma.com/investor-relations/webcast/>

For further information contact:

Dr Tom Duthy
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Chair

Mayne Pharma Group Limited

ABN 76 115 832 963

[maynepharma.com](https://www.maynepharma.com)

1538 Main North Road, Salisbury South, SA 5106 Australia



ASX Announcement

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.